Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.43 |
| ▸ | ITGAV | P06756 | 13/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028375 | 0.79 | ITGB3 (0.46) | ITGB3ITGAV | |
| SCHEMBL5024074 | 0.78 | ITGB3 (0.48) | ITGB3ITGAVKCNH2HSD17B10TSHR | |
| SCHEMBL5023988 | 0.75 | ITGB3 (0.47) | ITGB3ITGAVHSD17B10KDM4EGAA | |
| SCHEMBL6425808 | 0.74 | ITGB3 (0.74) | ITGB3ITGAVCXCR3 | |
| SCHEMBL6439935 | 0.74 | ITGB3 (0.50) | ITGB3ITGAVJAK1KCNH2CXCR3 | |
| SCHEMBL5025438 | 0.73 | ITGB3 (0.53) | ITGB3ITGAVKDM4ESMN1; SMN2 | |
| SCHEMBL6439941 | 0.73 | ITGB3 (0.49) | ITGB3ITGAVJAK1KCNH2CXCR3 | |
| SCHEMBL8139051 | 0.70 | SMN1; SMN2 (0.53) | JAK1KCNH2KDM4EGAAMAPT | |
| SCHEMBL383139 | 0.67 | NOS2 (0.58) | ITGB3ITGAVKCNH2HSD17B10KDM4E | |
| SCHEMBL9383756 | 0.67 | NPC1 (0.53) | JAK1KCNH2KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885JAK1 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.